Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPL026 IM and IV in Healthy Volunteers
NCT05644093Phase 1Completed
- Sponsor
- Small Pharma
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of SPL026 in major depressive disorder (MDD) (2 arms), sponsored by Small Pharma. Primary endpoints: Laboratory Biochemistry at Day 1, Incidence of Treatment-Emergent Adverse Events at Day 15 and 6 more. Started Jan 2023; status: completed.
02
Drugs
SPL026
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT05644093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05644093.